Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-658-0600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.34 million
Profitability
Miscellaneous
Employees332
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Karyopharm Therapeutics (NASDAQ:KPTI) Frequently Asked Questions
What is Karyopharm Therapeutics' stock symbol?
Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."
How were Karyopharm Therapeutics' earnings last quarter?
Karyopharm Therapeutics Inc (NASDAQ:KPTI) issued its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.71) EPS for the quarter, topping the Zacks' consensus estimate of ($0.97) by $0.26. The business had revenue of $9.49 million for the quarter. Karyopharm Therapeutics had a negative return on equity of 154.75% and a negative net margin of 2,138.80%. View Karyopharm Therapeutics' Earnings History.
When is Karyopharm Therapeutics' next earnings date?
What price target have analysts set for KPTI?
6 Wall Street analysts have issued 12 month target prices for Karyopharm Therapeutics' stock. Their forecasts range from $5.00 to $32.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $19.3333 in the next twelve months. This suggests a possible upside of 69.3% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.
What is the consensus analysts' recommendation for Karyopharm Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.
What are Wall Street analysts saying about Karyopharm Therapeutics stock?
Here are some recent quotes from research analysts about Karyopharm Therapeutics stock:
- 1. According to Zacks Investment Research, "Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. " (7/13/2019)
- 2. HC Wainwright analysts commented, "We base our $30 price target on probability-adjusted revenue forecasts for selinexor. We use a net present value of our revenue forecast through 2026, apply a 50% probability of success (POS) for selinexor in penta refractory multiple myeloma, a 35% POS for selinexor in combination treatment for multiple myeloma, and a 25% POS for selinexor in DLBCL. We use a 4x P/S multiple and an estimated early stage pipeline value of $0.86/ share. Our P/S multiple of 4x is in-line with Karyopharm’s peers that range between 2-5x." (2/27/2019)
Has Karyopharm Therapeutics been receiving favorable news coverage?
Media stories about KPTI stock have been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Karyopharm Therapeutics earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Karyopharm Therapeutics.
Who are some of Karyopharm Therapeutics' key competitors?
Some companies that are related to Karyopharm Therapeutics include Reata Pharmaceuticals (RETA), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Genmab A/S (GMAB), Biohaven Pharmaceutical (BHVN), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK), Amicus Therapeutics (FOLD), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Portola Pharmaceuticals (PTLA) and Akcea Therapeutics (AKCA).
What other stocks do shareholders of Karyopharm Therapeutics own?
Who are Karyopharm Therapeutics' key executives?
Karyopharm Therapeutics' management team includes the folowing people:
- Dr. Michael G. Kauffman, Co-Founder, CEO & Director (Age 56)
- Dr. Sharon Shacham, Co-Founder, Pres, Chief Scientific Officer & Co-Chairman of Scientific Advisory Board (Age 49)
- Mr. Christopher Brett Primiano, Exec. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 38)
- Dr. Mansoor Raza Mirza, Clinical Consultant, Member of Scientific Advisory Board & Director (Age 58)
- Mr. Michael P. Mason, Sr. VP, CFO & Treasurer (Age 44)
Who are Karyopharm Therapeutics' major shareholders?
Karyopharm Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.31%), Orbimed Advisors LLC (5.08%), Vanguard Group Inc. (4.82%), Point72 Asset Management L.P. (4.19%), Candriam Luxembourg S.C.A. (3.20%) and Emerald Advisers LLC (2.43%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.
Which institutional investors are selling Karyopharm Therapeutics stock?
KPTI stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., First Midwest Bank Trust Division, Connor Clark & Lunn Investment Management Ltd., Morgan Stanley, Emerald Advisers LLC, Trexquant Investment LP and BNP Paribas Arbitrage SA. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Ltd Chione, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.
Which institutional investors are buying Karyopharm Therapeutics stock?
KPTI stock was acquired by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Point72 Asset Management L.P., Nuveen Asset Management LLC, Vanguard Group Inc., D. E. Shaw & Co. Inc., BlackRock Inc., A.R.T. Advisors LLC and Private Capital Advisors Inc.. View Insider Buying and Selling for Karyopharm Therapeutics.
How do I buy shares of Karyopharm Therapeutics?
Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Karyopharm Therapeutics' stock price today?
One share of KPTI stock can currently be purchased for approximately $11.42.
How big of a company is Karyopharm Therapeutics?
Karyopharm Therapeutics has a market capitalization of $707.13 million and generates $30.34 million in revenue each year. The company earns $-178,410,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.
What is Karyopharm Therapeutics' official website?
How can I contact Karyopharm Therapeutics?
Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]
MarketBeat Community Rating for Karyopharm Therapeutics (NASDAQ KPTI)
| Community Ranking: | | 3.1 out of 5 ( ) |
| Outperform Votes: | | 412 (Thanks for Voting!) |
| Underperform Votes: | | 262 (Thanks for Voting!) |
| Total Votes: | | 674 |
